What is the Emerging Therapies Collaborative
The Multiple Sclerosis Emerging Therapies Collaborative has been organized to provide timely, evidence-based resources regarding the known benefits and risks of newly emerging, FDA-approved medications for multiple sclerosis (MS). The Collaborative's goal is to promote optimal, individualized MS treatment by facilitating effective communication and medical decision making for persons affected by MS and health care professionals. This group, which includes the MS Coalition, the American Academy of Neurology, and the Multiple Sclerosis VA Centers of Excellence East and West, will post information and resources for each of the therapies as they gain FDA approval.
Who are the participating organizations
The Multiple Sclerosis Emerging Therapies Collaborative includes the MS Coalition, the American Academy of Neurology, and the VA Multiple Sclerosis Centers of Excellence East and West read more...
October 15, 2012 - Clinician and Patient templates for Teriflunomide (Aubagio) are now available.read more...
August 24, 2012 - On August 15, 2012, an additional change to the natalizumab (Tysabri) prescribing information, recommending that patients with a negative serum anti-JCV antibody test result should be retested every 6 months. read more...
July 26, 2012 - On July 23, 2012, the Food and Drug Administration (FDA) issued a safety update regarding the risk of seizures in patients taking dalfampridine (Ampyra), noting that seizures are a known risk of dalfampridine therapy and that the majority of seizures reported in postmarketing surveillance occurred within days to weeks of starting the drug in patients with no prior history of seizures.read more...
The Multiple Sclerosis Emerging Therapies Collaborative – which includes the MS Coalition, the American Academy of Neurology, and the VA Multiple Sclerosis Centers of Excellence East and West – is committed to developing and disseminating timely, evidence-based resources to persons affected by multiple sclerosis and health care professionals, in order to promote optimal, individualized treatment of the disease by facilitating effective communication and medical decision-making. Launched in 2011, the Collaborative has as its priority to provide information on MS-specific, US Food and Drug Administration (FDA)-approved treatments that have entered the market since 2010. Previously-approved medications will be reviewed in the event of new safety or efficacy data that significantly affect their use in MS treatment.